Pelubiprofen is a new member of the class of non-steroidal anti-inflammatory drugs for the treatment of back pain and pain in rheumatic musculoskeletal disorders

On December 18, 2024, a meeting of the Expert Council was held to discuss approaches to the treatment of non-specific back pain and pain in rheumatic musculoskeletal disorders. It was noted that non-steroidal anti-inflammatory drugs (NSAIDs) remain the mainstay of therapy for inflammation-related pain and that optimal therapy should provide a balance between high efficacy and good tolerability in each patient. A new NSAID, pelubiprofen (Pelubio®), has been registered in the Russian Federation. According to research data, its efficacy is comparable to that of non-selective and selective NSAIDs and at the same time the drug has a high safety profile. The resolution of the Expert Council states that this medicine can be prescribed within the framework of Russian clinical practice, considering the registered indications for pelubiprofen and the clinical guidelines adopted in Russia for the treatment of acute and chronic non-specific back pain, radiculopathy, osteoarthritis (including gonarthrosis and coxarthrosis) and rheumatoid arthritis.

Authors

Institutions

Publication Details

Journal
Modern Rheumatology Journal
Published
2025-02-18
DOI
https://doi.org/10.14412/1996-7012-2025-1-116-123
Primary Topic
Inflammatory mediators and NSAID effects
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Pelubiprofen is a new member of the class of non-steroidal anti-inflammatory drugs for the treatment of back pain and pain in rheumatic musculoskeletal disorders

Vorob'eva Ov, А. М. Лила, Maxim V. Churyukanov, Е. В. Екушева et al.
Modern Rheumatology Journal
Inflammatory mediators and NSAID effects
article

Pelubiprofen is a new member of the class of non-steroidal anti-inflammatory drugs for the treatment of back pain and pain in rheumatic musculoskeletal disorders

Vorob'eva Ov, А. М. Лила, Maxim V. Churyukanov, Е. В. Екушева, V. V. Afanasyev, Alena I. Zagrebneva, D. A. Iskra, О.С. Давыдов, В. А. Парфенов, Е. С. Филатова, Е. Р. Баранцевич, Mikhail Lvovich Kukushkin, Т. В. Адашева, Andrey E. Karateev, Л. И. Алексеева, Andrey Petrovich Rachin, V.A. Shirokov
article en

Abstract

On December 18, 2024, a meeting of the Expert Council was held to discuss approaches to the treatment of non-specific back pain and pain in rheumatic musculoskeletal disorders. It was noted that non-steroidal anti-inflammatory drugs (NSAIDs) remain the mainstay of therapy for inflammation-related pain and that optimal therapy should provide a balance between high efficacy and good tolerability in each patient. A new NSAID, pelubiprofen (Pelubio®), has been registered in the Russian Federation. According to research data, its efficacy is comparable to that of non-selective and selective NSAIDs and at the same time the drug has a high safety profile. The resolution of the Expert Council states that this medicine can be prescribed within the framework of Russian clinical practice, considering the registered indications for pelubiprofen and the clinical guidelines adopted in Russia for the treatment of acute and chronic non-specific back pain, radiculopathy, osteoarthritis (including gonarthrosis and coxarthrosis) and rheumatoid arthritis.

Modern Rheumatology JournalVol. 19(1)
Sechenov University (RU), First Pavlov State Medical University of St. Petersburg (RU), Pirogov Russian National Research Medical University (RU), Russian Medical Academy of Continuous Professional Education (RU), Ministry of Health of the Russian Federation (RU), Association of Rheumatologists of Russia (RU), Research Institute of General Pathology and Pathophysiology, the Russian Academy of Medical Sciences (RU), Medical Technologies (Czechia) (CZ), Saint Petersburg State Pediatric Medical University (RU)
Openalex Percentile: Top 96%
Inflammatory mediators and NSAID effects
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.